Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew T Wheeler

Showing results (161-170 of 191) with videos related to

Pageof 20
Sort By:
Nature Medicine|June 5, 2019
Identification of rare-disease genes using blood transcriptome sequencing and large control cohortsLaure Frésard, Craig Smail, Nicole M Ferraro, et al.
Circulation|December 5, 2024
Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic CardiomyopathyJoshua K Meisner, Aaron Renberg, Eric D Smith, et al.
Nature Communications|June 26, 2019
Pathologic gene network rewiring implicates PPP1R3A as a central regulator in pressure overload heart failurePablo Cordero, Victoria N Parikh, Elizabeth T Chin, et al.
Lancet (London, England)|May 4, 2010
Clinical assessment incorporating a personal genomeEuan A Ashley, Atul J Butte, Matthew T Wheeler, et al.
Circulation|March 17, 2025
Correction to: Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic CardiomyopathyJoshua K Meisner, Aaron Renberg, Eric D Smith, et al.
JAMA|February 1, 2022
Prevalence and Cumulative Risk of Familial Idiopathic Dilated CardiomyopathyGordon S Huggins, Daniel D Kinnamon, Garrie J Haas, et al.
JAMA Cardiology|September 6, 2023
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical TrialChristoffer Rasmus Vissing, Anna Axelsson Raja, Sharlene M Day, et al.
Circulation. Heart Failure|December 10, 2019
Baseline Characteristics of the VANISH CohortAnna Axelsson Raja, Ling Shi, Sharlene M Day, et al.
Nature Medicine|September 24, 2021
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y Ho, Sharlene M Day, Anna Axelsson, et al.
Nature|November 12, 2025
GREGoR: accelerating genomics for rare diseasesMoez Dawood, Ben Heavner, Marsha M Wheeler, et al.
Pageof 20

Showing results (161-170 of 191) with videos related to

Sort By:
Pageof 20
Nature Medicine|June 5, 2019
Identification of rare-disease genes using blood transcriptome sequencing and large control cohortsLaure Frésard, Craig Smail, Nicole M Ferraro, et al.
Circulation|December 5, 2024
Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic CardiomyopathyJoshua K Meisner, Aaron Renberg, Eric D Smith, et al.
Nature Communications|June 26, 2019
Pathologic gene network rewiring implicates PPP1R3A as a central regulator in pressure overload heart failurePablo Cordero, Victoria N Parikh, Elizabeth T Chin, et al.
Lancet (London, England)|May 4, 2010
Clinical assessment incorporating a personal genomeEuan A Ashley, Atul J Butte, Matthew T Wheeler, et al.
Circulation|March 17, 2025
Correction to: Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic CardiomyopathyJoshua K Meisner, Aaron Renberg, Eric D Smith, et al.
JAMA|February 1, 2022
Prevalence and Cumulative Risk of Familial Idiopathic Dilated CardiomyopathyGordon S Huggins, Daniel D Kinnamon, Garrie J Haas, et al.
JAMA Cardiology|September 6, 2023
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical TrialChristoffer Rasmus Vissing, Anna Axelsson Raja, Sharlene M Day, et al.
Circulation. Heart Failure|December 10, 2019
Baseline Characteristics of the VANISH CohortAnna Axelsson Raja, Ling Shi, Sharlene M Day, et al.
Nature Medicine|September 24, 2021
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y Ho, Sharlene M Day, Anna Axelsson, et al.
Nature|November 12, 2025
GREGoR: accelerating genomics for rare diseasesMoez Dawood, Ben Heavner, Marsha M Wheeler, et al.
Pageof 20